CNS drug development roundtable with Annovis and Clene

Alzheimer’s, Parkinson's, ALS, MS --these are all serious or fatal neurodegenerative diseases that lack effective treatments. Thankfully, innovative companies are developing promising, novel therapies in the field. Maria Maccecchini is founder and CEO of Annovis Bio, which is focused on improving axonal transport. Robert Glanzman is Chief Medical Officer of Clene, whose approach relies on nanotherpauetics. Our discussion centers on the particular challenges in developing CNS drugs, how Maria and Robert have steered their companies throughout the last two challenging years, and what they hoped to achieve during the JP Morgan Healthcare Conference. The companies’ approaches --one drug increases energy and the other speed-- could be synergistic. If that ends up being the case, remember it all started here on the HealthBiz podcast.

The HealthBiz podcast is available on Spotify, Apple Podcasts, Google Podcasts, YouTube and  many more services.

By healthcare business consultant David E. Williams, president of Health Business Group.